Skip to main content
Benjamin Brooks, MD, Neurology, Charlotte, NC

Benjamin Rix Brooks MD

Neuromuscular Medicine


Medical Director

Join to View Full Profile
  • 1010 Edgehill Rd NCharlotte, NC 28207

  • Phone+1 704-446-1900

  • Fax+1 704-466-6084

Dr. Brooks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Neurology, 1976 - 1978
  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1972 - 1974
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1970 - 1972
  • Harvard Medical School
    Harvard Medical SchoolClass of 1969

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2008 - 2025
  • WI State Medical License
    WI State Medical License 1982 - 2025
  • MD State Medical License
    MD State Medical License 1976 - 1992
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2020

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (Edaravone)
    Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (Edaravone)August 15th, 2022
  • Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (Edaravone)
    Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (Edaravone)June 29th, 2022
  • #AAN2022 – US Real-World Data Show Radicava Boosts Survival Rate
    #AAN2022 – US Real-World Data Show Radicava Boosts Survival RateApril 5th, 2022
  • Join now to see all

Grant Support

  • Tamoxifen Therapy On Mean Percent Predicted Isometric Strength In ALSNational Center For Research Resources2005
  • Phase II Study Of Hu23f2g In Acute Excerbations Of Multiple SclerosisNational Center For Research Resources1998–2002
  • Phase I Trial Of R-Methubdnf Given By Daily Injection To Patients With ALSNational Center For Research Resources1996
  • Phase I Safety And Tolerability Study Of BDNF In Patients With ALSNational Center For Research Resources1995–1996

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: